Projects per year
Deubiquitylating enzymes (DUBs) play a vital role in the ubiquitin pathway by editing or removing ubiquitin from their substrate. As breakthroughs within the ubiquitin field continue to highlight the potential of deubiquitylating enzymes as drug targets, there is increasing demand for versatile high-throughput (HT) tools for the identification of potent and selective DUB modulators. Here we present the HT adaptation of the previously published MALDI-TOF–based DUB assay method. In a MALDI-TOF DUB assay, we quantitate the amount of mono-ubiquitin generated by the in vitro cleavage of ubiquitin chains by DUBs. The method has been specifically developed for use with nanoliter-dispensing robotics to meet drug discovery requirements for the screening of large and diverse compound libraries. Contrary to the most common DUB screening technologies currently available, the MALDI-TOF DUB assay combines the use of physiological substrates with the sensitivity and reliability of the mass spectrometry–based readout.
|Number of pages||26|
|Early online date||2 Nov 2020|
|Publication status||Published - Dec 2020|
- Deubiquitylating enzymes
- Drug discovery
- Mass spectrometry
- Target validation
ASJC Scopus subject areas
- Biochemistry, Genetics and Molecular Biology(all)
FingerprintDive into the research topics of 'High-throughput matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry–based deubiquitylating enzyme assay for drug discovery'. Together they form a unique fingerprint.
- 1 Finished
MRC PPU Covid Research
18/10/20 → 17/07/21